Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry Sells 2,500 Shares

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 2,500 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $7.52, for a total value of $18,800.00. Following the sale, the general counsel now owns 72,250 shares of the company’s stock, valued at approximately $543,320. The trade was a 3.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Benjamin Landry also recently made the following trade(s):

• On Friday, December 6th, Benjamin Landry sold 19,268 shares of Health Catalyst stock. The stock was sold at an average price of $8.32, for a total value of $160,309.76.

Health Catalyst Price Performance

Shares of HCAT traded down $0.47 during mid-day trading on Friday, reaching $6.89. The company had a trading volume of 477,428 shares, compared to its average volume of 533,036. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The company has a market capitalization of $419.24 million, a P/E ratio of -5.10 and a beta of 1.36. Health Catalyst, Inc. has a twelve month low of $5.42 and a twelve month high of $11.41. The company’s 50-day moving average is $7.81 and its 200-day moving average is $7.52.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.22) earnings per share. On average, equities analysts anticipate that Health Catalyst, Inc. will post -0.33 EPS for the current year.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors have recently added to or reduced their stakes in HCAT. Principal Financial Group Inc. increased its holdings in shares of Health Catalyst by 6.9% during the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after buying an additional 1,907 shares in the last quarter. Rhumbline Advisers boosted its stake in Health Catalyst by 9.1% in the second quarter. Rhumbline Advisers now owns 91,111 shares of the company’s stock worth $582,000 after purchasing an additional 7,589 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in Health Catalyst by 276.3% in the second quarter. Los Angeles Capital Management LLC now owns 213,693 shares of the company’s stock worth $1,365,000 after purchasing an additional 156,908 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Health Catalyst by 1.3% during the second quarter. Acadian Asset Management LLC now owns 734,257 shares of the company’s stock worth $4,690,000 after purchasing an additional 9,697 shares during the last quarter. Finally, ClariVest Asset Management LLC increased its stake in shares of Health Catalyst by 1.2% in the second quarter. ClariVest Asset Management LLC now owns 285,627 shares of the company’s stock valued at $1,825,000 after buying an additional 3,302 shares in the last quarter. 85.00% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

HCAT has been the topic of several research analyst reports. Royal Bank of Canada raised their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. Evercore ISI raised their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research report on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.45.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.